# PT-141: Research Overview > PT-141 / Bremelanotide Research Overview | Research Peptide Fundamentals — Research Peptide Fundamentals research peptides guide to PT-141, or bremelanotide, with melanocortin mechanism, clinical evidence, and cautions. **IDENTITY FILE 04 / MELANOCORTIN AGONIST** The research code and the nonproprietary name bremelanotide point to one central melanocortin record, bounded by population and indication. ## The short version PT-141 is the research code for bremelanotide, a cyclic peptide that acts in the brain through melanocortin receptors. Unlike medicines that mainly change blood flow, bremelanotide targets neural pathways involved in sexual desire and arousal. The approved product Vyleesi contains bremelanotide, but approval is specific to acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not a general approval for sexual enhancement or for use in every population [22]. Randomized trials found statistically significant improvements in desire and desire-related distress in the studied population [20]. Brain-imaging research supports a central mechanism, showing altered processing of sexual cues after melanocortin-4 receptor agonism [19]. The main tolerability issue is nausea; flushing and headache are also prominent in long-term data [21]. A transient blood-pressure rise and pigment changes are label-level cautions [22]. Code name and nonproprietary name should be unified for evidence counting, while approved product and unregulated “research chemical” material should never be assumed equivalent. ## What it is Bremelanotide is a synthetic cyclic heptapeptide related to alpha-melanocyte-stimulating hormone. The identity ledger connects PT-141, PT 141, bremelanotide, bremelanotide acetate, and BMT. These terms can lead to the same active compound record, although a salt designation and a product presentation still matter when interpreting a specific study or label. This is a useful case of name evolution. Early development literature may favor the code PT-141, while clinical trials and regulatory documents use bremelanotide. Searching only one term creates a false split in the evidence. At the same time, a vial advertised with the code name outside the regulated supply chain does not inherit the identity, purity, or labeling evidence of an approved prescription product. Compound reconciliation links scientific records; it does not validate a product. ## How it works Bremelanotide activates melanocortin receptors, chiefly MC4R and also MC3R, in hypothalamic and limbic circuits. The working model is that MC4R signaling engages neural pathways involved in sexual motivation and arousal, including dopaminergic processing. This central mechanism distinguishes it from peripheral vasodilator approaches. It is not described in this corpus as a direct testosterone therapy or a growth-hormone peptide. In a randomized crossover functional-imaging study of 31 premenopausal women with hypoactive sexual desire disorder, MC4R agonism increased desire for up to 24 hours and changed brain responses to erotic stimuli, including connectivity between the amygdala and insula [19]. Preclinical evidence adds nuance: in female Syrian hamsters, bremelanotide did not enhance conditioned sexual reward and did not change melanocortin-receptor messenger RNA in the studied reward circuit [18]. The two studies ask different questions and should not be framed as direct replication. ## What the research shows Two phase 3 RECONNECT trials enrolled 1,267 premenopausal women with hypoactive sexual desire disorder. Over 24 weeks, bremelanotide produced statistically significant improvement in the integrated desire score and reduction in desire-related distress relative to placebo [20]. The effect sizes were 0.35 points for the desire endpoint and -0.33 points for the distress item, so statistical significance should be read alongside the scale and the defined population [20]. A 52-week open-label extension enrolled 684 women. Improvements were sustained and no new safety signals emerged, while the most common drug-related adverse events were nausea at 40.4%, flushing at 20.6%, and headache at 12.0% [21]. The regulatory label supplies the approved indication, pharmacokinetics, and warnings, including transient increases in blood pressure and a contraindication in uncontrolled hypertension or known cardiovascular disease [22]. These sources concern regulated bremelanotide in clinical settings, not material sold merely under the PT-141 code. ## Reported effects, cautions & safety **The reports in this paragraph are anecdotal, not clinical evidence.** Community accounts commonly describe stronger desire, greater physical arousal, heightened sensitivity, or more intense pleasure. Some off-label male users report spontaneous erections, while other users report no benefit at all. Frequently discussed adverse experiences include nausea, flushing, headache, injection-site irritation, tingling, drowsiness, and skin or gum darkening with repeated exposure. The accounts are uncontrolled and cannot establish frequency or suitability outside the studied population. Controlled and regulatory sources make the main cautions clearer. Nausea was the leading long-term tolerability issue, followed by flushing and headache [21]. The label warns that blood pressure can rise transiently and excludes uncontrolled hypertension and known cardiovascular disease from the approved use [22]. Melanocortin activity can also produce focal hyperpigmentation, which may not fully reverse [22]. Approval applies to a specific diagnosis in premenopausal women; use in men, postmenopausal women, or for generalized enhancement lies outside that approved evidence frame. ## Where it fits in Research Peptide Fundamentals PT-141 is the clearest code-to-name reconciliation in the collection. PT-141 and bremelanotide should not be treated as two independent compounds when tallying studies. The code remains useful for discovery, while the nonproprietary name dominates later clinical and regulatory records. Vyleesi is a product name, not a separate molecule or a license to generalize beyond its label. Mechanistically, PT-141 is the outlier here. It does not belong to the GH/IGF-1 axis shared by CJC-1295 and tesamorelin, and it is not an incretin agonist like semaglutide. Its evidence concerns central melanocortin signaling and a defined sexual-desire disorder. This sharp separation is why a multi-compound hub needs more than a list of effects: without receptor, population, and name reconciliation, unrelated findings can be made to look comparable when they are not. --- An independent identity-first digest of peptide literature—source reconciliation and study context, never a product desk or clinical directive.